Current Issue


Glycemic control worse over time in type 2 patients who decline insulin, study finds

In adults with uncontrolled type 2 diabetes who initially declined insulin versus those who initially accepted, median time to an HbA1c level below 7.0% was 50 months versus 38 months.

Diabetes associated with significantly increased risk of mortality in cardiomyopathy

Patients with diabetes and mild-to-moderate cardiomyopathy had higher mortality risk than nondiabetic patients with severe cardiomyopathy, suggesting that they may benefit from implantable cardioverter defibrillators, according to the study authors.

Roux-en-Y gastric bypass associated with better long-term diabetes outcomes than sleeve gastrectomy

While both procedures were associated with high rates of type 2 diabetes remission, the rate of remission five years after surgery was about 10% higher in patients who had gastric bypass than in those who had sleeve gastrectomy.

MKSAP quiz: Preconception testing

This month's quiz asks readers to provide preconception counseling to a patient with type 1 diabetes with no known microvascular or macrovascular complications.

Spotlight on glycemic control and patient age

Recent studies found higher HbA1c levels in younger patients with diabetes compared to older ones, as well as differences in medication therapy by age.

In type 2 diabetes, SGLT-2 inhibitors reduce risk for major kidney outcomes

The data suggest that renoprotection from sodium-glucose cotransporter-2 (SGLT-2) inhibitors may not require the presence of diabetes or albuminuria and may be effective even in patients with worse renal function, an ACP Journal Club commentary said.

In type 2 diabetes, early metformin plus vildagliptin reduced treatment failure vs a stepwise approach

Despite this study's findings, clinicians should continue to follow guidelines and use metformin as the first-line drug intervention, then select from other drug classes when there is a compelling indication, advised an ACP Journal Club commentary.

Insulin pumps recalled due to incorrect dosing

The manufacturer of the pumps, which deliver insulin to patients with type 1 diabetes, has received a total of 26,421 complaints and is aware of 2,175 injuries and one death.